Meet the Team
Chu Swee Yeok
Chair & Founding Partner
Swee Yeok is the Chair and Founding Partner of AGP, and is the Senior Advisor to EDBI. She is an experienced business leader with over 35 years of expertise in management, investments, and strategy development. Prior to this she was the CEO and President of EDBI since 2009, responsible for the development and execution of investment strategies at EDBI. Championing the management of multi billion-dollar assets in funds and direct investments spanning US, Europe, China, SEA and Singapore in healthcare, digital technologies, financial services, advanced manufacturing, sustainability, and other high growth sectors, she successfully transformed EDBI from a passive state-owned fund management company into an active, reputable internationally recognized investor on a global stage. Prior to EDBI, she was the founding CEO of Bio*Capital, a billion-dollar global biomedical healthcare fund, which made significant investments in US, Europe and China, including seeding many innovative start ups and joint venture companies in Singapore. She was a pioneer of Singapore’s biomedical initiatives including establishing the first global biotech funds at EDB in 1980s. Additionally, whilst at EDB and A*STAR where she helmed concurrent senior positions, she drove the conceptualization of strategic plans and their successful execution through multiple agencies, laying the necessary foundations for growing the healthcare biomedical sector into one of the major contributors of Singapore’s economy today. Swee Yeok brings with her deep experience and extensive network into the local and overseas ecosystems of industries that she has been involved in over the last 35 years. She serves on the board of NHG, the largest healthcare group in Singapore as well as several other private and public companies. She also advises research entities like A*STAR on research translation and commercialization strategies. Ms Chu graduated with BSc Honors in Biochemistry from NUS and from Harvard Business School’s Executive Advanced Management Program.
Basil Lui, PhD
Founding Partner
Basil has over 25 years of experience as the Founding Partner of AGP. Prior to this, he was an Advisor and Managing Partner at EDBI where he oversaw investments in Healthcare and Emerging Technologies. Basil was a key member of EDBI’s Investment Committee, and on the healthcare front, he was involved in several investments for EDBI, including Doctor Anywhere a full-stack online-offline healthcare service; Hummingbird Bioscience a clinical-stage precision medicine company; MiRXES a developer of RNA early disease detection tests; US2.ai an AI software platform for echocardiography to fight heart disease; and a pre-covid investment into mRNA vaccine platform Moderna (NASDAQ:MRNA). Basil has a strong interest in regenerative technologies that can restore cellular health and resilience. Additionally, Basil drove early stage deep-tech fund-of-funds investments at EDBI, covering regional healthcare funds, and as a LP Advisory Committee member in various portfolio funds, worked closely in partnership with the funds to invest in Singapore and the region. He also spearheaded EDBI’s investments in areas that would have an impact to the future of healthcare and the bioeconomy such as synthetic biology, gene edits, robotics, AI, blockchain, AR and VR. Basil pioneered EDBI's post-investment value creation and communications efforts, ensuring strong support to portfolio companies through market access, talent recruitment, strategic financing, partnership & guidance; and is often a speaker in global technology events and panels. Prior to EDBI, Basil was a McKinsey consultant covering South East Asia, an Adjunct Associate Professor at the Keppel-NUS Corporate Laboratory, the APAC President of a global semiconductor electronic design automation company, an Assistant Professor at National University of Singapore Electrical & Computer Engineering, and a post-doctoral researcher at the Cambridge University Engineering Department. Basil is the inventor of several patents and holds a BA (1st class), MA and PhD from the University of Cambridge. He was awarded a Commonwealth scholarship, a Singapore Government Public Service Commission scholarship, and a Research Fellowship from Trinity College Cambridge.
Davian Sim
Managing Director, Investments
Davian is the MD, Investments of AGP. Prior to this he was the Senior Principal of Investments at EDBI where he was responsible for originating, leading and negotiating investments in areas such as Manufacturing/Advanced Manufacturing, Healthcare Services and Technology. Specifically, Davian successfully led several healthcare investment transactions in services and industrial manufacturing such as Dontia Alliance, a pan-Asian specialist focused dental services company; Meiban, an Asian based medtech manufacturer; and Esco Lifesciences, a global medical equipment and devices brand and manufacturer. He also represented EDBI as a board observer in several of its portfolio companies. Before EDBI, he was responsible for strategic investments and divestiture at Aalst-Wilmar, an associate company of Wilmar International focused on industrial chocolate and cocoa and prior to that, focused on growth and buyout transactions at BXR Group, an international private investment group specialised on large ticket investments in infrastructure, real estate and resources and; middle market investments in healthcare and education. Davian started his investment career at Credence Partners (now known as Altara Ventures), a Southeast Asian small/mid cap focused private equity fund focused on Consumer, Services, Logistics, Manufacturing and Technology. Davian’s overall deal experience ranges widely, from minority stake growth transactions and leveraged buyous, to M&As and joint ventures. Throughout his career, he was also seconded to various portfolio companies to assist with commercial negotiations, operations and strategic business development activities. Davian began his career at PrimePartners Corporate Finance, a boutique investment banking outfit advising clients on capital market transactions. He is a qualified CPA (Australia) and graduated with a Master of Applied Finance from Macquarie University, Sydney and a Bachelor of Commerce from The Australian National University, Canberra.
Warren Tan, PhD
Investments
Warren is part of the AGP Investments team. He was previously at SGInnovate, where he covered corporate engagement and venture deals under the healthcare and agrifood verticals. Earlier, he was an innovation consultant with Alcimed, where he supported corporates in innovation sourcing and technology landscaping. Warren graduated from the National University of Singapore with a PhD and BSc (1st class) in Life Sciences. In his doctoral research, he developed quantitative LC-MS panels, and screened for heart disease biomarkers in clinical cohorts. He also holds a BSc (1st class) in Applied Accounting from Oxford Brookes University and is continuing to hone his skills in finance as a CFA program participant.
Gabriel Siow
Investments
Gabriel is part of the AGP Investments team. Prior to this, he spent time with Capital Code where he worked on several transactions including capital raising, M&A, and financial due diligence in the Industrials and Food & Agriculture sectors. Before Capital Code, he was with Abacus Capital where he was involved in dozens of transactions in a wide range of industries spanning Hospitality, F&B, Agriculture, Energy, and the Services sector. Gabriel graduated from Singapore Management University with a Bachelor of Business Management (cum laude), with a major in Finance.
Chris Koh
Portfolio Management
Chris Koh is a multifaceted professional with a strong background in entrepreneurship, marketing, operations, and trading. He holds a Bachelor of Commerce with double majors in Economics and Finance from Monash University, Melbourne. Chris has essential experience in an SME, where he played a key role in marketing, operations, and business development with various industry stakeholders. He has also previously worked as an independent trader, specializing in funding arbitrage, market analysis, and risk-reward decision-making across diverse financial markets.
Operations
Jude Tan
Director, Finance & Compliance
Jude is responsible for establishing and managing all aspects of finance, compliance and operational matters in relation to AGP and its funds. He started his career in public accounting with one of the Big 4 accounting firms in Singapore, during which he spent 3 years in a secondment program to the firm’s London practice. Following that, Jude was Vice President in the Enterprise Strategy department of GIC, the sovereign wealth fund of Singapore. In that role, he supported senior management in tackling complex cross- functional issues such as sustainability (ESG), organisational design and human capital management. Prior to AGP, Jude was a pioneering team member of Greenwillow Capital Management, a licensed fund management company in Singapore. He was responsible for all middle and back office functions of the company. Jude graduated from the Nanyang Technological University with a Bachelor of Accountancy (First Class Honours), with a second major in Marketing. He is also a Chartered Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW).
Venture Partners
Shawn Tan
Venture Partner
Shawn is an investment professional with over 20 years’ experience in both private and public equity investments. He is currently the Managing Director of Axon Alpha Advisors, a family office investor with a global mandate and healthcare portfolio which includes medical devices, oncology drug development and digital health solutions. Prior to this, Shawn led private equity, technology focused investments at Novo Tellus Capital and EDBI. At Novo Tellus he led investments into companies providing advanced automation solutions for biomedical end products and at EDBI he was responsible for the Strategic Growth Programme, which invested in large local enterprises to help them compete globally. Some of his previous healthcare investment investments included Biosensors Ltd which specializes in interventional cardiology and critical care procedures, Hummingbird Bioscience, which develops breakthrough therapies for cancer treatments, Inovio Pharmaceutical Inc, which develops immunotherapies for cancer and infectious diseases, BotMD, a digital health company. He was also involved in Hyphens, a local medical product company expanding its operations in the region. Shawn other past appointments include Asia Pacific Head for Sharjah Asset Management, where he oversaw investments for UAE government funds. He was also an Investment Director at Westcomb Financial Group, a corporate finance company listed on the Singapore Stock Exchange. Earlier in his career, Shawn was part of the team that drove the commercialization and development of technology enterprises at the Agency for Science Technology and Research (A*STAR). He holds a Bachelor's with Honours Degree in Genetics and Molecular Biology from Glasgow University, UK, and a Master’s Degree in Applied Finance from Adelaide University, Australia.
Ong Jeong Shing
Venture Partner
Jeong Shing (JS) has over 15 years of global healthcare experience across corporate pharma, technology management and venture capital, including incubating and building early stage life science companies. He was Partner at EDBI, the strategic venture arm of the Economic Development Board of Singapore, leading healthcare investments in biotech, medtech, digital health and life science tools, as well as Fund of Fund investments. His investment track record and network span key geographies including USA, China, Singapore and Southeast Asia, which is complemented by his operational experience in helping portfolio companies pursue international expansion, particularly into Singapore and its surrounding Asia Pacific region. Prior to EDBI, JS oversaw investments at Venturecraft, a Singapore based boutique venture capital firm and multi-family office focusing on tech and healthcare. He successfully set up a digital health incubator supported by the Singapore government and nurtured several successful local start up companies such as Mirxes, US2.ai, Hearti Labs and Aktivo. He also established a life science accelerator in Hangzhou China, to help portfolio companies accelerate product and clinical development and gain rapid access to the Chinese market. Before starting his venture career, JS led process development and scale up at Glaxosmithkline, working across UK, US and Singapore and on multiple blockbassets in oncology and respiratory diseases. JS earned First Class Honours Degrees in Bioengineering and Chemical Engineering from the National University of Singapore, and holds an MBA with distinction from the University of Cambridge, specializing in Private Equity.